Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 62 versus FENTANYL CITRATE.
Head-to-head clinical analysis: FENTANYL 62 versus FENTANYL CITRATE.
FENTANYL-62 vs FENTANYL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Fentanyl is a potent synthetic opioid agonist that primarily acts on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and euphoria. It also interacts with kappa and delta opioid receptors to a lesser extent. By binding to these receptors, fentanyl inhibits adenylate cyclase, reduces cAMP production, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels, resulting in hyperpolarization and reduced neurotransmitter release.
For analgesia: 50-100 mcg IV/IM every 1-2 hours as needed. For anesthesia: 2-50 mcg/kg IV. For PCA: 10-20 mcg IV with 5-10 min lockout. Transdermal: 12-100 mcg/h patch every 72 hours; start at 25 mcg/h in opioid-naive patients.
Initial adult dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; for anesthesia induction 2-20 mcg/kg IV.
None Documented
None Documented
3–7 hours (terminal elimination half-life; prolonged in elderly, hepatic impairment, or with continuous infusion due to redistribution).
Terminal elimination half-life: 3-12 hours (mean 4-6 hours in adults). Context: Prolonged with hepatic impairment, elderly, or continuous infusion (context-sensitive half-life increases with infusion duration).
Renal (primarily as metabolites, <10% unchanged; ~75% total metabolites in urine), fecal (~9% total metabolites).
Primarily hepatic metabolism (N-dealkylation to norfentanyl and other metabolites); less than 10% excreted unchanged in urine; approximately 9% excreted in feces via biliary elimination.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist